Increased titer of anti-β2-glycoprotein I IgG antibody among factor V Leiden carriers during oral contraceptive use

Contraception

Volumn 69, Issue 1, 2004, Pages 27-30

  Poka R ^a   Vad, S ^a   Lakos, G ^a   Bereczki, Z ^a   Kiss, E ^a   Sipka, S ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Antiphospholipid antibodies; Factor V Leiden; Oral contraception

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 5 LEIDEN; CIPROPTERONE; ETHINYLESTRADIOL; GESTAGEN; IMMUNOGLOBULIN G ANTIBODY; LEVONORGESTREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE CARRIER; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL CONTRACEPTION; RISK FACTOR; SCREENING TEST; THROMBOEMBOLISM; TITRIMETRY; WILD TYPE;

EID: 17644430305     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2003.08.016     Document Type: Article

References (12)

1. Vad S., Lakos G., Kiss E., et al. Antiphospholipid antibodies in young women with and without oral contraceptive use. Blood Coag Fibrinolys. 14:2003;57-60.
2. Balogh I., Póka R., Pfliegler G., et al. High prevalence of Factor V Leiden mutation and 20210A prothrombin variant in Hungary. Thromb Haemost. 81:1999;660-661.
3. Bertina R.M., Koelman B.P., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67.
4. Jick H., Jick S.S., Gurewich V., et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with different progestagen components. Lancet. 46:1995;1589-1593.
5. Ginsburg K.S., Liang M.H., Newcomer L., et al. Anticardiolipin antibodies and the risk for ischaemic stroke and venous thrombosis. Ann Int Med. 117:1992;997-1002.
6. Brey R.L., Abbott R.D., Curb D., et al. β2-glycoprotein I-dependent anticardiolipin antibodies and risk of ischaemic stroke and myocardial infarction. The Honolulu Heart Program. Stroke. 32:2001;1701-1706.
7. Bloemenkamp K.W., Rosendaal F.R., Helmerhorst F.M., Vandenbroucke J.P. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. 160:2000;49-52.
8. Girolami A., Zanon E., Zanardi S., et al. Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies. Blood Coag Fibrinolys. 7:1996;497-501.
9. Vandenbroucke J.P., van der Meer F.J.M., Helmerhorst F.M., Rosendaal F.R. Factor V Leiden should we screen oral contraceptive users and pregnant women? BMJ. 313:1996;1127-1130.
10. 2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood. 91:1998;1999-2004.
11. Heinmann L.A.J., Kluft C., Spannagl M., de Maat M.P.M. The association between extrinsic activated protein C resistance and venous thromboembolism in women. Contraception. 66:2002;297-304.
12. Meinardi J.R., Henkens C.M.A., Heringa M.P., van der Meer J. Acquired APC resistance related to oral contraceptives and pregnancy and its possible implications for clinical practice. Blood Coag Fibrinolys. 8:1997;152-154.